Investigation of individualized treatment for AMD patient with QOL improvement

• Project/Area Number: 26462641
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Ophthalmology
• Research Institution: Kyushu University
• Principal Investigator: Oshima Yuji 九州大学, 大学病院, 特別教員 (00536237)
• Co-Investigator(Kenkyū-buntansha): 石橋 達朗 九州大学, 大学病院, 病院長 (30150428)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 眼科学 / 分子生物学 / 眼生化学 / 臨床研究 / 滲出型加齢黄斑変性 / 加齢黄斑変性 / 遺伝子多型 / ポリープ状脈絡膜血管症 / Quality of vision

Outline of Final Research Achievements

Although there was no correlation between visual acuity change after AMD treatment and genetic polymorphism, there was significant correlation between central retinal thickness change and genetic polymorphism. The effect of anti-VEGF therapy for AMD patient may concern to inflammation, because this polymorphism related to inflammation.
The visual acuity and central macular thickness after aflibercept treatment with polypoidal choroidal vasculopathy (PCV)patient, one type of AMD, improved significantly compared to baseline. This result suggested that aflibercept mono therapy is effective for PCV treatment. The score of QOL of AMD patient was significantly improved after anti-VEGF treatment. This results suggested that anti-VEGF therapy for AMD patients are effective morphologically and functionally.

Research Products

• [Journal Article] Low-frequency coding variants in CETP and CFB are associated with susceptibility of exudative age-related macular degeneration in the Japanese population. (2016)
  • Author(s): Momozawa Y, Akiyama M, Kamatani Y, Arakawa S, Yasuda M, Yoshida S, Oshima Y, Mori R, Tanaka K, Mori K, Inoue S, Terasaki H, Yasuma T, Honda S, Miki A, Inoue M, Fujisawa K, Takahashi K, Yasukawa T, Yanagi Y, Kadonosono K, Sonoda KH, Ishibashi T, Takahashi A, Kubo M.
  • Journal Title: Hum Mol Genet. Volume: 25 Pages: 5027-5034
  • DOI: 10.1093/hmg/ddw335
  • Peer Reviewed / Open Access
• [Journal Article] Full thickness macular hole case after intravitreal aflibercept treatment. (2015)
  • Author(s): Oshima Y, Apte RS, Nakao S, Yoshida S, Ishibashi T.
  • Journal Title: BMC Ophthalmol Volume: 15 Issue: 1 Pages: 30-30
  • DOI: 10.1186/s12886-015-0021-3
  • Peer Reviewed / Open Access
• [Presentation] Two-year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients (2017)
  • Author(s): Yuji Oshima, Satomi Shiose, Kumiko Kano, Shigeo Yoshida, Tatsuro Ishibashi, Koh-hei Sonoda
  • Organizer: 32nd Asia-Pacific Academy of Ophthalmology Congress
  • Place of Presentation: Singapore
  • Year and Date: 2017-03-03
• [Presentation] One-year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO study (2016)
  • Author(s): Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Koh-hei Sonoda, Tatsuro Ishibashi
  • Organizer: ARVO
  • Place of Presentation: Seattle, USA
  • Year and Date: 2016-05-03
  • Int'l Joint Research
• [Presentation] One-year Outcomes following Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in Japanese Patients: The APOLLO study (2016)
  • Author(s): Yuji Oshima, The APOLLO study group
  • Organizer: The Association for Research in Vision and Ophthalmology (ARVO)
  • Place of Presentation: Seattle, USA
  • Year and Date: 2016-05-01
• [Presentation] ポリープ状脈絡膜血管症に対するアフリベルセプトの治療効果に関する研究：6ヶ月成績 (2015)
  • Author(s): 大島裕司
  • Organizer: 第54回網膜硝子体学会・第32回眼循環学会
  • Place of Presentation: 東京都
  • Year and Date: 2015-12-04